Bausch Health Companies Inc. [NYSE: BHC] gained 4.96% or 1.09 points to close at $23.06 with a heavy trading volume of 5405810 shares. The company report on March 3, 2022 that Bausch Health Announces Participation in Upcoming Investor Conferences.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced that the Company will participate at two upcoming investor conferences.
Joseph C. Papa, chairman and chief executive officer; Sam Eldessouky, executive vice president and chief financial officer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022 at 12:50 p.m. ET and at the Barclays Global Healthcare Conference 2022 in Miami on March 15, 2022 at 11:15 a.m. ET.
It opened the trading session at $22.53, the shares rose to $23.08 and dropped to $22.315, the range by which the price of stock traded the whole day. The daily chart for BHC points out that the company has recorded -18.11% loss over the past six months. However, it is still -11.4% lower than its most recent low trading price.
If we look at the average trading volume of 3.97M shares, BHC reached to a volume of 5405810 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Bausch Health Companies Inc. [BHC]:
BofA Securities have made an estimate for Bausch Health Companies Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on March 24, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price from $26 to $42. The new note on the price target was released on February 17, 2021, representing the official price target for Bausch Health Companies Inc. stock. Previously, the target price had yet another raise from $25 to $30, while Piper Sandler kept a Neutral rating on BHC stock.
The Average True Range (ATR) for Bausch Health Companies Inc. is set at 0.94, with the Price to Sales ratio for BHC stock in the period of the last 12 months amounting to 0.97. Price to Free Cash Flow for BHC in the course of the last twelve months was 7.08 with Quick ratio for the last quarter at 0.90.
Trading performance analysis for BHC stock
Bausch Health Companies Inc. [BHC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.36. With this latest performance, BHC shares dropped by -6.79% in over the last four-week period, additionally sinking by -18.11% over the last 6 months – not to mention a drop of -30.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BHC stock in for the last two-week period is set at 47.09, with the RSI for the last a single of trading hit 50.54, and the three-weeks RSI is set at 45.80 for Bausch Health Companies Inc. [BHC]. The present Moving Average for the last 50 days of trading for this stock 24.61, while it was recorded at 22.42 for the last single week of trading, and 27.13 for the last 200 days.
Bausch Health Companies Inc. [BHC]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Bausch Health Companies Inc. [BHC] shares currently have an operating margin of +18.69 and a Gross Margin at +55.31. Bausch Health Companies Inc.’s Net Margin is presently recorded at -11.24.
Return on Equity for this stock declined to -441.96, with Return on Assets sitting at -3.14.
Bausch Health Companies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.
Bausch Health Companies Inc. [BHC]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BHC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bausch Health Companies Inc. go to 8.70%.
An analysis of insider ownership at Bausch Health Companies Inc. [BHC]
There are presently around $5,791 million, or 66.80% of BHC stock, in the hands of institutional investors. The top three institutional holders of BHC stocks are: ICAHN CARL C with ownership of 34,721,118, which is approximately 1.794% of the company’s market cap and around 2.30% of the total institutional ownership; PAULSON & CO. INC., holding 25,839,035 shares of the stock with an approximate value of $567.68 million in BHC stocks shares; and NOMURA HOLDINGS INC, currently with $417.21 million in BHC stock with ownership of nearly 23.485% of the company’s market capitalization.
Positions in Bausch Health Companies Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 184 institutional holders increased their position in Bausch Health Companies Inc. [NYSE:BHC] by around 29,645,528 shares. Additionally, 153 investors decreased positions by around 24,013,004 shares, while 83 investors held positions by with 209,936,423 shares. The mentioned changes placed institutional holdings at 263,594,955 shares, according to the latest SEC report filing. BHC stock had 75 new institutional investments in for a total of 13,280,752 shares, while 43 institutional investors sold positions of 5,799,900 shares during the same period.